马扎哌汀 | 134208-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 马扎哌汀
• 英文名称: 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine
• 英文别名: Mazapertine；[3-[[4-[2-(1-Methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]-piperidine；piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
• CAS: 134208-17-6
• 化学式: C₂₆H₃₅N₃O₂
• 分子量: 421.583
• InChiKey: ZKZFPRUSWCYSGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  马扎哌汀 以45的产率得到
  参考文献：
  名称：

  4-arylpiperazines and 4-arylpiperidines

  摘要：

  本文披露了一种新型抗精神病药物，其一般式为I：##STR1##。

  公开号：

  US05569659A1
• 作为产物：
  描述：

  3-(氯甲基)苯甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 马扎哌汀
  参考文献：
  名称：

  Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D₂, Serotonin 5-HT_1A, and Adrenergic α₁ Receptors

  摘要：

  New antipsychotic drugs are needed because current therapy is ineffective for many schizophrenics and because treatment is often accompanied by extrapyramidal symptoms and dyskinesias. This paper describes the design, synthesis, and evaluation of a series of related (aminomethyl)benzamides in assays predictive of antipsychotic activity in humans. These compounds had notable affinity for dopamine D-2, serotonin 5-HT1A, and alpha(1)-adrenergic receptors. The arylpiperazine 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine (mazapertine, 6) was chosen because of its overall profile for evaluation in human clinical trials. The corresponding 4-arylpiperidine derivative 67 was also highly active indicating that the aniline nitrogen of 6 is not required for activity. Other particularly active structures include homopiperidine amide 14 and N-methylcyclohexylamide 31.

  DOI：

  10.1021/jm970164z

文献信息

• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors
  申请人：——

  公开号：US20040014768A1

  公开（公告）日：2004-01-22

  Novel chromenone derivatives of the formula I 1 in which Y, X, R 1 , R 2 , R 3 and n are as defined in claim 1, as inhibitors of the 5-HT 1A receptor and of the dopamine D 2 receptor.

  新型的咖啡酮衍生物，其化学式为I1，在该化学式中Y、X、R1、R2、R3和n的定义如权利要求书中所述，作为5-HT1A受体和多巴胺D2受体的抑制剂。
• Arylpiperazine derivatives and their use as psychotropic agents
  申请人：——

  公开号：US20040014972A1

  公开（公告）日：2004-01-22

  The invention relates to arylpiperazine derivatives of formula (I), wherein R 1 , R 2 , A, B, Ar and n have the given meanings. 1

  该发明涉及式(I)的芳基哌嗪衍生物，其中R1、R2、A、B、Ar和n具有给定的含义。
• Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
  申请人：——

  公开号：US20040019044A1

  公开（公告）日：2004-01-29

  The invention relates to heterocyclic aminoalkylpyridine derivatives of the formula I 1 where R 1 is the radical of a heterocycle having 1 to 3 ring structures, where each ring structure is saturated, unsaturated or aromatic and optionally fused to other ring structures to give a fused ring system and the heterocycle has a total of 1 to 4 N, O and/or S atoms in the ring structures and is optionally monosubstituted, disubstituted or trisubstituted by one or more of the groups —A, —OR 4 , —N(R 4 ) 2 , —NO 2 , —CN, Hal, —COOR 4 , —CON(R 4 ) 2 , —COR 4 , ═O; R 2 is a phenyl group which is optionally monosubstituted, disubstituted, trisubstituted, tetrasubstituted or pentasubstituted by one or more of the groups Hal, —A, —O—A, —NO 2 or —CN, or is a thienyl group which is optionally monosubstituted or disubstituted by one or more of the groups Hal, —A, —O—A, —NO 2 , —CN or thienyl; R 3 is H, —A, —CO—A, —C(R 4 ) 2 R 2 , —C(R 4 ) 2 -pyridinediyl-R 2 ; R 4 is H or —A; A is C 1 -C 6 -alkyl, where 1 to 7 hydrogen atoms are optionally replaced by fluorine; —X— is —O—, —S—, sulfinyl, sulfonyl, —C(R 4 ) 2 —; —Y— is —[C(R 4 ) 2 ] n —; —Z— is —C(R 4 ) 2 —; Hal is F, Cl, Br or I; n is 1, 2, 3 or 4; and their tolerable salts and solvates and their use as medicaments.

  该发明涉及公式I1的杂环氨基烷基吡啶衍生物，其中R1是具有1到3个环结构的杂环的基团，每个环结构是饱和的、不饱和的或芳香的，并且可选择地与其他环结构融合以形成融合环系统，杂环在环结构中总共有1到4个N、O和/或S原子，并且可选择地通过一个或多个基团—A、—OR4、—N(R4)2、—NO2、—CN、Hal、—COOR4、—CON(R4)2、—COR4、═O进行单取代、双取代或三取代；R2是苯基，该苯基可选择地通过一个或多个基团Hal、—A、—O—A、—NO2或—CN进行单取代、双取代、三取代、四取代或五取代，或者是噻吩基，该噻吩基可选择地通过一个或多个基团Hal、—A、—O—A、—NO2、—CN或噻吩进行单取代或双取代；R3是H、—A、—CO—A、—C(R4)2R2、—C(R4)2-吡啶基-R2；R4是H或—A；A是C1-C6-烷基，其中1到7个氢原子可选择地被氟取代；—X—是—O—、—S—、砜基、磺酰基、—C(R4)2—；—Y—是—[C(R4)2]n—；—Z—是—C(R4)2—；Hal是F、Cl、Br或I；n是1、2、3或4；以及它们的可耐受盐和溶剂化合物及其作为药物的用途。
• [EN] SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE<br/>[FR] DÉRIVÉS DE PYRAZINONE SUBSTITUÉS À UTILISER COMME MÉDICAMENT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2007135131A1

  公开（公告）日：2007-11-29

  (EN) The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective &agr;2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.(FR) La présente invention concerne des dérivés de pyrazinone substitués selon la formule générale (I), un sel d'addition acide ou basique pharmaceutiquement acceptable de ceux-ci, une forme stéréochimiquement isomère de ceux-ci, une forme N-oxyde de ceux-ci ou un sel d'ammonium quaternaire de ceux-ci, les variables étant définies dans la revendication 1, ayant une activité d'antagoniste de récepteur adrénergique α2C sélective. L'invention concerne en outre leur préparation, les compositions les contenant et leur utilisation comme médicament. Les composés selon l'invention sont utiles pour la prévention et/ou le traitement des troubles du système nerveux central, les troubles de l'humeur, les troubles de l'anxiété, les troubles liés au stress associés à la dépression et/ou à l'anxiété, les troubles cognitifs, les troubles de la personnalité, les troubles schizo-affectifs, la maladie de Parkinson, les démences du type Alzheimer, les conditions de douleur chronique, les maladies neurodégénératives, les troubles de l'addiction, les troubles de l'humeur et les dysfonctionnements sexuels.

  本发明涉及根据一般公式（I）的取代吡嗪酮衍生物，其具有药学上可接受的酸或碱盐、立体化异构体、N-氧化物形式或季铵盐形式，其中变量在权利要求1中定义，具有选择性α2C-肾上腺素受体拮抗活性。它还涉及它们的制备、包含它们的组合物以及它们作为药物的用途。根据本发明的化合物对于预防和/或治疗中枢神经系统障碍、情绪障碍、焦虑障碍、与抑郁和/或焦虑相关的应激障碍、认知障碍、人格障碍、分裂情感障碍、帕金森病、阿尔茨海默型痴呆、慢性疼痛症状、神经退行性疾病、成瘾障碍、情绪障碍和性功能障碍方面是有用的。